Comparison
6q Terminal Deletion Syndrome C4304514 vs 17 20 Lyase Deficiency Isolated Included CN372394
Clinical comparison between 6Q Terminal Deletion Syndrome and 17 20 Lyase Deficiency Isolated Included CN372394 for differential diagnosis and treatment planning.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
17 20 Lyase Deficiency Isolated Included CN372394
0-16
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
17 20 Lyase Deficiency Isolated Included CN372394
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
17 20 Lyase Deficiency Isolated Included CN372394
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
17 20 Lyase Deficiency Isolated Included CN372394
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
17 20 Lyase Deficiency Isolated Included CN372394
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 17-20-lyase-deficiency-isolated-included-CN372394 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 17 20 Lyase Deficiency Isolated Included CN372394 | Discriminating power |
|---|---|---|---|
| Developmental pattern | Developmental delay and variable congenital features may be present from birth. | Development is not established as primarily affected; sex-steroid-related findings may appear from infancy through adolescence. | Moderate |
| Physical features | Variable structural or growth features may accompany the chromosomal deletion. | Features, if present, more plausibly relate to sex-hormone deficiency; exact features are not established here. | Moderate |
| Endocrine presentation | No specific endocrine pattern is established by the supplied description. | Isolated 17,20-lyase deficiency may impair sex-steroid production, but confirmation is required. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital anomalies with developmental delay
A chromosomal cause is more consistent with the supplied congenital genetic description.
Moderate
Abnormal chromosomal study
A confirmed terminal 6q deletion supports this diagnosis over an endocrine disorder.
High
No primary sex-steroid concern
Absence of an endocrine presentation makes the deletion syndrome relatively more likely, but does not exclude other conditions.
Low
Choose 17 20 Lyase Deficiency Isolated Included CN372394 when
Suspected disorder of sex development
An endocrine steroid-synthesis disorder fits better than a chromosomal deletion when sex-hormone deficiency is the main concern.
Moderate
Pubertal delay or undervirilization
These scenarios may prompt evaluation for 17,20-lyase deficiency, but are not definitive.
Moderate
Normal chromosomal testing
A normal karyotype or microarray lowers suspicion for 6q deletion but does not prove lyase deficiency.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 17 20 Lyase Deficiency Isolated Included CN372394 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May show deletion of terminal chromosome 6q. | No characteristic chromosomal deletion is expected. | A confirmed deletion supports the left diagnosis; a normal result does not diagnose the right condition. |
| Sex-steroid and precursor profile | No specific pattern is established. | May suggest impaired sex-steroid synthesis, but cutoffs are not supplied. | Abnormal results require specialist interpretation and are not a diagnosis alone. |
| Targeted genetic testing | May corroborate a 6q terminal deletion when clinically indicated. | May assess genes implicated in isolated lyase deficiency when selected by a specialist. | Gene choice and variant interpretation belong to qualified clinicians; sparse source data limit certainty. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Often a lifelong congenital condition with variable developmental impact; exact prognosis is not established.
- Factors
- Deletion extent, associated anomalies, developmental support, and comorbidities may influence outcome.
17 20 Lyase Deficiency Isolated Included CN372394
- Outcome
- Potentially lifelong endocrine condition; outcome and fertility implications are not established from the supplied data.
- Factors
- Age at recognition, hormone findings, genetic confirmation, and specialist management may matter.
Time frame: From birth or childhood into adulthood, with uncertainty because long-term data are not supplied.
Accurate diagnosis, associated conditions, access to specialist care, and individual variation are key.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental complications | Delays and learning or functional needs may be substantial. Primary developmental complications are not established from the supplied data. Support needs should be individualized; severity labels alone do not predict outcome. |
| Growth or puberty concerns | Growth or physical variation may occur, but specifics are not established. Pubertal development or sex-steroid-dependent features may be affected. Neither finding should be treated as diagnostic without appropriate testing. |
| Associated congenital or endocrine issues | Variable congenital features may require multidisciplinary care. Possible adrenal or gonadal implications need specialist assessment; exact risks are not established here. Do not infer cortisol status, fertility, or treatment from this comparison. |
Patient education highlights
- HighDifferent causes
One condition is a chromosomal deletion; the other is an endocrine disorder. They are not interchangeable diagnoses.
- HighTesting limits
An abnormal laboratory or genetic result needs clinician interpretation and does not automatically confirm either diagnosis.
- MediumIndividual course
Both may be chronic and severe in supplied classifications, but features and outcomes vary and are incompletely documented here.